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Background: Several studies have suggested a cancer risk reduction in statin users although the evidence remains
weak for stomach cancer. The purpose of this study was to use an exact-matching case–control design to examine
the risk of gastric cancer associated with the use of statins in a cohort of patients with diabetes.
Methods: Cases were defined as patients with incident gastric cancer identified by International Classification of
Diseases 16.0 ~ 16.9 recorded at Samsung Medical Center database during the period of 1999 to 2008, at least 6
months after the entry date of diabetes code. Each gastric cancer case patient was matched with one control
patient from the diabetes patient registry in a 1:1 fashion, blinded to patient outcomes.
Results: A total of 983 cases with gastric cancer and 983 controls without gastric cancer, matched by age and sex,
were included in the analysis. The presence of prescription for any statin was inversely associated with gastric
cancer risk in the unadjusted conditional logistic regression model (OR: 0.18; 95% CI: 0.14 – 0.24; P < .0001).
Multivariate analysis using conditional logistic regression with Bonferroni’s correction against aspirin indicated a
significant reduction in the risk of gastric cancer in diabetes patients with statin prescriptions (OR: 0.21; 95% CI: 0.16
– 0.28; P < .0001). After adjustment for aspirin use, a longer duration of statin use was associated with reduced risk
of gastric cancer, with statistical significance (P<.0001).
Conclusions: A strong inverse association was found between the risk of gastric adenocarcinoma and statin use in
diabetic patients.
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Gastric cancer is the leading cause of cancer death
worldwide, with an incidence of 18.9/100,000 per year
and a mortality rate of 14.7/100,000 per year [1]. It is
also the most common cancer type in Korea. Despite the
worldwide prevalence of gastric cancer, its chemopre-
vention has been relatively poorly studied.
Several large-scale epidemiology studies have high-
lighted the potential anti-tumor effect of statins on
various solid tumors. Statins are synthetic 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhi-
bitors that are commonly used drugs for the treatment
of hypercholesterolemia. Statins inhibit the rate-limiting* Correspondence: wkkang@skku.edu
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reproduction in any medium, provided the orstep of the mevalonate pathway that produces mevalonic
acid, the precursor for the biosynthesis of isoprenoid
molecules such as cholesterol, dolichol, and ubiquinone.
Mevalonate-derived prenyl groups, farnesyl pyrophos-
phate (FPP), and geranylgeranyl pyrophosphate (GGPP)
facilitate essential intracellular functions of various pro-
teins such as Ras and Rho [1-3]. One of the first large-
scaled epidemiologic studies, the MECC (The Molecular
Epidemiology of Colorectal Cancer) study, demonstrated
that the use of statins for more than 5 years was asso-
ciated with a 47 percent relative reduction in the risk of
colorectal cancer, after adjustment for other known risk
factors such as age, sex, ethnic group, hypercholesterol-
emia, history of colorectal cancer in a first-degree rela-
tive, and level of vegetable consumption [4]. Although
the results from these studies support the hypothesis
that statins may reduce the risk of cancer, overall results
from observational studies still remain inconclusive,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation between statins and cancer occurrence [5].
Recently, several interesting studies have analyzed the
risk of cancer in patients with diabetes mellitus (DM)
who were on statin therapy. Among these studies, the
Hong Kong group analyzed a DM cohort of 5,276
patients and found a decreased risk of cancer in non-
statin users and co-presence of high LDL cholesterol
[6]. In contrast, statin non-users with low LDL choles-
terol and albuminuria had a 4.9-fold risk for any
cancer when compared with statin users [6]. The same
research group also demonstrated that statins reduced
cancer risk in DM patients, potentially via normalizing
hydroxymethylgutaryl-CoA reductase (HMGCR) and the
insulin-like growth factor-1 (IGF-1) signaling pathway
[7]. In addition, statin use was associated with a signifi-
cant 38% reduction in the risk of hepatocellular carcin-
oma among DM patients [8]. For gastric cancer, a recent
meta-analysis demonstrated a potential protective effect
of statins, with median risk ratio of 0.59 (range, 0.40 –
0.88) [9]. A nested case control study reported an odds
ratio of 0.86 (95% CI, 0.72 – 1.02) for stomach cancer
based con 1,992 cases and 8,279 controls [10]. Neverthe-
less, the evidence remains weak and no large-scaled
epidemiologic studies have yet been conducted to specif-
ically analyze the risk of gastric cancer and its associ-
ation with statin use.
We undertook this study to examine the risk of gastric
cancer associated with the use of statins using an exact
matching case–control design nested in a cohort of
patients with diabetes. We also investigated the potential
association between duration of statin use and the risk
of gastric cancer.
Methods
We first identified a large cohort of patients with DM
who were treated at Samsung Medical Center. In this
study, study cases were defined as patients who were
diagnosed with gastric cancer at least 6 months after
the entry date of the diabetes code. Gastric cancer was
identified by International Classification of Diseases
16.0 ~ 16.9 recorded at Samsung Medical Center data-
base during the period of 1999 to 2008. Cases were
excluded if gastric cancer was diagnosed shortly after
or before the diagnosis of diabetes: any gastric cancer
cases diagnosed within 6 months of the diagnosis of dia-
betes were excluded from this study. All included cases
were pathologically or cytologically diagnosed at our
center. Each gastric cancer case patient was matched
with one control patient from the diabetes patient regis-
try, in a 1:1 fashion that was blinded to patient out-
comes. Matching variables were age (exact) and sex
at an index date, which was the date of the gastric
cancer diagnosis for each case. We excluded patientswho had no prescription record available in our database
or those who were followed up at our hospital for less
than 1 year.
Exposure to statins
Statin prescriptions were collected from our electronic
prescription record system. Statins included simvastatin,
atorvastatin, lovastatin, rosuvastatin, pitavastatin, pravas-
tatin, and cerivastatin. We collected the dates of filled
prescriptions, daily dose, number of days supplied, and
the number of pills per prescription. In the cases of sta-
tin prescribed before visiting Samsung Medical Center,
we utilized the electronic drug identification system at
our center, which identifies the drug and dosage to hos-
pital pharmacists upon consultation. As a routine prac-
tice, we consult all of the outside prescription drugs
with hospital pharmacists to verify identification of
drugs. We collected prescription information on aspirin,
nonstatin lipid-lowering medications (cholestyramine,
colestipol, and niacin), and triglyceride-lowering medica-
tions (clofibrate, fenofibrate, and gemfibrozil). Statin
users were defined as those who had statin filled pre-
scriptions for at least 6 months.
Clinical data validation
All of the inpatient and outpatient charts at Samsung
Medical Center, including the drug prescription system,
are currently electronic. After identification of cases and
controls, the following clinical data were collected from
the electronic medical chart system: date of diagnosis of
gastric cancer, stage according to AJCC 2002, Lauren
classification (intestinal, diffuse, and mixed), pathology,
smoking status (never smoker, smoker, not checked), lo-
cation, and Helicobacter pylori status.
Statistical analyses
Descriptive data are presented as means and propor-
tions, as well as by frequency, for continuous data and
categorical data, respectively. For univariate analysis,
conditional logistic regression analysis was used to iden-
tify the risk effect for gastric cancer because of matched
data. Conditional multiple logistic regression analysis
was used to detect the effect of statin use for gastric can-
cer after adjusting for aspirin use.
We investigated the statin duration-effect for gastric
cancer using conditional logistic regression by evaluating
the effect of the duration of any statin prescriptions
examined in the following categories: 0.5 – 1.0 year,
1.0 – 1.5 years, 1.5 – 2.0 years, greater than 2.0 years.
The filled prescription record for any statin during
the designated time period included both in-hospital
prescription and outside hospital filled prescriptions
identified in the medical record system. Bonferroni’s cor-
rection was used to correct inflation type I error due to
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nificance was 0.05. All data analyses were conducted
using SAS software, version 9.1.3 (SAS Institute, Inc.,
Cary, NC).
This study was reviewed and approved by the
Samsung Medical Center Institutional Review Board in
accordance with the Declaration of Helsinki.
Results
The diabetes cohort of 12,001 patients treated at
Samsung Medical Center between 1999 and 2008
included 1,106 potentially eligible patients in whom gas-
tric adenocarcinoma (including signet ring cell carcin-
oma) was identified during the study period. Of those
1,106 patients, 123 patients were excluded from the ana-
lysis due to lack of prescription records or insufficient
clinical data for gastric cancer. Thus, 983 cases with gas-
tric cancer and 983 controls without gastric cancer,
matched by age and sex, were included in the final ana-
lysis. All of the patients were of Korean ethnicity. The
mean age was 62.6 years in each cohort and 76.5% of the
study population were male (Table 1). Owing to the
exact matched pair analysis, the distributions of age and
sex were identical between the two cohorts. The pre-
scription data for statin and aspirin use are provided inTable 1 Demographic factors and filled prescription data
in cases with advanced gastric cancer (AGC) and matched
controls
Variables AGC (n=983) Control (n=983)
N % N %
Mean age, y 62.6 62.6
Sex
Men 752 76.5 752 76.5
Women 231 23.5 231 23.5
Statin user 99 10.1 367 37.3
Atorvastatin 31 31.3 143 39.0
Simvastatin 27 27.3 67 18.2
Rosuvastatin 11 11.1 59 16.1
Pravastatin 12 12.1 48 13.1
Pitavastatin 4 4.0 18 4.9
Others 14 14.1 32 8.7
Statin exposure duration (year)
0 - < 0.5 884 89.9 616 62.7
0.5 – 1.0 38 3.9 71 7.2
1.0 – 1.5 12 1.2 61 6.2
1.5 – 2.0 13 1.3 41 4.2
>2.0 36 3.7 194 19.7
Aspirin
Yes 184 18.7 347 35.3Table 1. The mean duration between the date of entry
into the diabetes cohort and the date of gastric cancer
index was 673 days.
Statin Use and the risk of gastric cancer
The presence of prescription for any statin was inversely
associated with gastric cancer risk in the unadjusted
conditional logistic regression model (OR: 0.18; 95% CI:
0.14 – 0.24; P < .0001; Table 2). After adjustment for a
potential confounder (aspirin), the association between
statins and the reduced risk of gastric cancer remained
significant (adjusted OR for aspirin: 0.61; 95% CI: 0.48 –
0.77; Table 2). Multivariate analysis using conditional
logistic regression with Bonferroni’s correction against
aspirin indicated a significant reduction in the risk of
gastric cancer in diabetes patients with statin prescrip-
tions (OR: 0.21; 95% CI: 0.16 – 0.28; P < .0001; Table 2).
Duration of statin Use and the risk of gastric cancer
We next examined the impact of duration of statin use
on gastric cancer risk. We subgrouped the patient co-
hort according to duration of statin use. Multivariate
analysis using conditional logistic regression, adjusting
for aspirin, indicated a significant reduction in the risk
of gastric cancer in diabetes patients in statin users
group when compared with the nonexposed group
(Table 3). Intriguingly, patients who had a longer dur-
ation of statin prescriptions had more reduced risk for
gastric cancer. Diabetes patients with less than 1 year of
statin use before the index date had an odds ratio (OR)
of 0.45; however, patients with statin use of more
than 2 years had an OR of 0.154 (95% CI: 0.09 – 0.26;
P < .0001). We analyzed the duration of statin use
and the risk of gastric cancer by performing a trend
test using conditional logistic regression analysis. After
adjustment for aspirin, we found that a longer durationTable 2 Effect of statin use on the incidence of gastric
cancer in diabetic patients
Univariable analysis
Variables Case Control P-value OR(95% CI)
Statin use 99 367 < .0001 0.183 (0.139 – 0.241)
Aspirin 184 347 < .0001 0.418 (0.337 – 0.518)
Other lipid
lowering agents
154 221 < .0001 0.148 (0.073 – 0.297)
Multivariable analysis
Variable Case Control P-value OR (95% CI)
Statin use 99 367 < .0001 0.211 (0.159 – 0.281)
Aspirin 184 347 < .0001 0.608 (0.478 – 0.773)
Other lipid
lowering agents
154 221 < .0001 0.156 (0.073 – 0.337)
Conditional logistic regression analysis was used.
Conditional multiple logistic regression analysis was used.
*Abbreviations: OR odds ratio.
Table 3 Duration of statin use and the risk of gastric




Case Control P-value+ OR (95% CI) +
0.5-1.0 38 71 < .0001 0.375 (0.216 – 0.651)
1.0-1.5 12 61 < .0001 0.138 (0.059 – 0.319)
1.5-2.0 13 41 < .0001 0.152 (0.058 – 0.400)




Case Control P-value OR (95% CI)
0.5-1.0 38 71 0.0016+ 0.446 (0.252 – 0.790) +
1.0-1.5 12 61 < .0001+ 0.143 (0.061 – 0.338) +
1.5-2.0 13 41 < .0001+ 0.178 (0.067 – 0.474) +
≥2.0 36 194 < .0001+ 0.154 (0.091 – 0.260) +
Aspirin 184 347 < .0001 0.618 (0.454 – 0.843)
Other lipid
lowering agents
154 221 < .0001 0.144 (0.053 – 0.392)
(reference category: Unexposed group).
Conditional logistic regression analysis was used.
+ ; Bonferroni’s correction was used to adjust inflation type I error due to
multiple testing.
(reference category: Unexposed group).
Conditional multiple logistic regression analysis was used.
+ ; Multiple conditional logistic regression with Bonferroni’s correction.
*Abbreviations: OR odds ratio.
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difference was statistically significant (P<.0001).
Statin Use and clinical features of gastric cancer
Among the 983 cases with gastric cancer, 99 patients
had begun statin therapy > 6 months prior to the diag-
nosis of gastric cancer. We performed a further associ-
ation analysis to characterize the clinical features of
statin users among gastric cancer patients (Table 4). Sta-
tin use was not significantly associated with smoking
status, Lauren classification, location, or the presence of
Helicobacter pylori. Intriguingly, the proportion of loca-
lized disease was significantly higher (81.8% vs. 74.0%;
statin user vs. non-user; P = 0.0400) in statin users
(81.8%) than in non-users (74.0%) (P=0.0400) (Table 4).
In addition, a trend toward favorable survival outcome
was evident in stain users when compared with non-
statin user gastric cancer patients (5-year OS, 89.3% vs.
73.0%; statin user vs. non-user; P=0.0873, Figure 1).
Discussion
A potential benefit of statin use has been suggested for
various tumor types, including colorectal cancer [4,11],
multiple myeloma [12], prostate cancer, breast cancer
[13,14], hepatocellular carcinoma [8], and lymphoma
[15]. This matched case–control study represents the
first study to indicate the existence of a strong inverseassociation between the risk of gastric adenocarcinoma
and statin use in diabetic patients. A trend toward stron-
ger risk reduction was seen with longer duration of sta-
tin prescriptions. The risk reduction observed with
statin use was about 78%, based on multivariate analysis.
No significant correlations were noted between gastric
cancer risk and prescriptions for aspirin.
Emerging evidence supports the potential role of sta-
tins as anti-cancer drugs in several tumor types. Statins
are synthetic 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors and are commonly
used drugs for the treatment of hypercholesterolemia. In
our previous report, we demonstrated that a low dose
lovastatin (equivalent to cardiovascular dose) induced
G1 phase cell cycle arrest and cell senescence via RhoA
modulation in cancer cells [16]. In addition, we reported
results from a phase II study that combined a cardiovas-
cular dose of simvastatin and standard FOLFIRI (irinote-
can, infusional 5-fluorouracil, leucovorin) as treatment
for metastatic colorectal cancer [17]. Lastly, we recently
demonstrated that the addition of 0.2 μM simvastatin
(equivalent to the human cardiovascular dose) to cetuxi-
mab significantly enhanced antitumor activity in KRAS
mutant colon cancer cells, but not in BRAFV600E mutant
colon cancer cells [18].
The insulin and IGF1 signals triggered through the
insulin receptors (IRs) and IGF1 receptor (IGF1R), re-
spectively, result in activation of the phosphotidylinositol
3-kinase/Akt signaling pathway and protein kinase C.
The IGF-1 and insulin signaling pathways are now
known to play important roles in tumor cell growth
that is correlated with diabetes risk and cancer [19]. The
potential anti-tumor effect of statins has been reported
for multiple IGF-1-dependent malignancies [20-22]. The
strong inverse correlation between statin use and colo-
rectal cancer [11], hepatocellular carcinoma [8], and
other types in patients with diabetes [6,7] led us to sur-
vey the risk of gastric cancer in this context. Previous
research has shown obesity, high body mass index, and
low plasma adiponectin levels to have an association
with an increased risk of gastric cancer, although the evi-
dence is still inconclusive [23-25]. However, statins may
plausibly exert an anti-tumor effect by modulating the
IGF pathway in gastric cancer, especially in the subgroup
of patients with diabetes. The risk of gastric cancer
in statin users among diabetes patients should be pro-
spectively confirmed for its definite role as a chemopre-
ventive agent.
The strengths of our study would be its large patient
cohort, the diagnosis of gastric cancer at a single center,
statin exposure data collected from a single database,
and the exact matched case–control paired analysis. Due
to the importance of pathologic classification of gastric
cancer, we excluded all cases which were not gastric
Table 4 Statin use in gastric cancer patients
Variables Statin User Non-Statin User P value
N % N %
Sex
Men 71 71.7 681 77.0 .2365
Women 28 28.3 203 23.0
Lauren classification
Intestinal 22 22.2 283 33.8 .1351
Diffuse 67 67.7 518 61.9
Mixed 4 4.0 36 4.3
Missing information 6 6.0 47 5.3
Pathology
W/D adenocarcinoma 26 26.3 142 16.0 .1461 (adenoca vs signet ring)
M/D adenocarcinoma 39 39.4 357 40.3
P/D adenocarcinoma 21 21.2 251 28.3
Signet ring cell carcinoma 13 13.1 134 15.4
Smoking
Never-smoker 51 51.5 391 44.2 .3037
Smoker 47 47.5 472 53.4
Missing information 1 1 21 2.4
Location
Cardia 6 6.1 51 5.8
Body ~ antrum 91 91.9 817 92.5 .9660
Whole, multifocal 2 2.0 15 1.7
Missing information 0 0 1 0.1
Helicobacter Pylori
Present 44 44.4 331 37.4 .1897
Absent 41 41.4 405 45.8
Missing information 14 14.2 148 16.7
Stage
Localized (stage I/II) 81 81.8 642 72.6 .0400
Advanced (stage III/IV) 16 16.2 226 25.6
Missing information 2 2.0 16 1.8
*Abbreviations: W/D well differentiated, M/D moderately differentiated, P/D poorly differentiated.
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exposure data were retrieved from our electronic med-
ical record system, which comprises all inpatient and
outpatient clinics. Hence, the prescription database is
relatively accurate. Nevertheless, our study is limited by
the observational retrospective nature of its study de-
sign. Other tentative risk factors for gastric adenocarcin-
oma, such as BMI, adenopectin levels, or dietary factors,
were not available for correlative analyses. The adjusted
odds ratio for gastric cancer was relatively low, confer-
ring about a 70 ~ 80% risk reduction by statin use in
diabetic patients in our study. This odds ratio is lower
than those reported for other cancer types, which ranged
from 20 – 60% risk reduction [4,8,11]. The retrospective
nature of the analysis also could present potential con-
founders such as prescription bias for statins in thegastric cancer patient cohort. However, the matched
case–control pairs were identified from a large patient
pool with diabetes, which may minimize this type of
bias, especially by eliminating those cases with diabetes
entry after the index date for gastric cancer. Another
potential bias for our observations would be the inherent
bias from our patient population, all of whom visited a
larger tertiary hospital in Korea instead of a private
clinic for diabetes control. This patient pool may be
more attentive to their health condition than others who
visited the tertiary hospital for gastric cancer treatment,
and thus might have led to an increased detection rate
for statin use in diabetes group. Hence, our analysis
should be cross-validated in other hospital settings. In
addition, our observation that lower incidence of gastric
cancer in statin users might be confounded by LDL
Statin use > 1 year (N=73)
Statin use < 1 year (N=85)
Control (N= 895)
P = 0.0873
Figure 1 Survival according to statin use.
Lee et al. BMC Cancer 2012, 12:596 Page 6 of 7
http://www.biomedcentral.com/1471-2407/12/596cholesterol. Several epidemiological studies have reported
that low plasma LDL cholesterol levels are associated with
an increased risk of cancer [26-29]. Therefore, patients
who were prescribed of statins might have higher LDL
cholesterol level, which might be associated with
decreased cancer risk.
Another limitation of our study is that due to retro-
spective nature of the study, the interval of endoscopy
was not controlled. In Korea and Japan, endoscopy is
recommended as a nationwide cancer screening pro-
gram after age of 40. In this particular cohort, the me-
dian time for endoscopy interval (2 years) and mean
duration between the date of entry into the diabetes co-
hort and gastric cancer index (673 days) are nearly the
same, suggesting that the possibility of preexisting can-
cer at the time of diabetes cohort registry cannot be
excluded. There was no difference in endoscopy inter-
vals between statin user and non-statin user in this co-
hort. In addition, the drug use in this study was defined
as any periods before diagnosis of gastric cancer and
therefore any periods after the diagnosis was classified as
non-use of statins. Our definition of use of statins pre-
sumes that gastric cancer does not occur after the use of
statin. Hence, longer duration of use of statins itself was
related with less chance of being diagnosed with gastric
cancer. Thus, testing the duration-effect relationship
may not mean more than the overall effect of statin use
on the risk of gastric cancer. To further validate the im-
pact of duration of statin use on gastric cancer incidence
would be to validate the “exact case control study” using
statins and their effect on cardiovascular disease or cor-
onary artery disease [30].
Statin use was not significantly associated with other
variables such as grade of differentiation, smoking
status, location, or the presence of Helicobacter pylori.However, gastric cancer found in statin users had an
increased likelihood for localized disease (P = 0.040).
One of the conceivable reasons for this type of finding
would be that a statin user might have been more com-
pliant for gastroscopy screening, which led to early de-
tection. In addition, the survival of gastric cancer
patients who had used statins for more than 6 months
demonstrated favorable survival (5-year OS, 89.3% vs.
73.0%; statin user vscpg non-user; P=0.0873, Figure 1)
when compared with non-statin users. The impact
of statin use on survival of gastric cancer needs to be
externally validated in order to draw a more defini-
tive conclusion.
Conclusion
In this study, we conducted a large exact-matched case–
control study in patients with diabetes. We demon-
strated that statin use may considerably reduce the
risk of gastric adenocarcinoma. Although external valid-
ation is needed, a lower incidence of gastric cancer was
evident in statin users. The anti-tumor effect of simvas-
tatin as a chemopreventive agent and/or anti-tumor
agent will be evaluated through ongoing trials (i.e.,
NCT# 00944463, NCT# 01099085).
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